Global IL-17 Inhibitors for Psoriasis Market Growth 2026-2032
The global IL-17 Inhibitors for Psoriasis market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.
IL-17 inhibitors for psoriasis are a class of biologic drugs designed to target and block the activity of interleukin-17 (IL-17), a pro-inflammatory cytokine that plays a critical role in the pathogenesis of psoriasis. By inhibiting IL-17, these drugs reduce the excessive immune response and help control the symptoms of moderate to severe plaque psoriasis. Examples of IL-17 inhibitors include secukinumab, ixekizumab, brodalumab and so on.
United States market for IL-17 Inhibitors for Psoriasis is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for IL-17 Inhibitors for Psoriasis is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for IL-17 Inhibitors for Psoriasis is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key IL-17 Inhibitors for Psoriasis players cover UCB, Eli Lilly, Novartis, Ortho Dermatologics, LEO Pharma, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the ?IL-17 Inhibitors for Psoriasis Industry Forecast? looks at past sales and reviews total world IL-17 Inhibitors for Psoriasis sales in 2025, providing a comprehensive analysis by region and market sector of projected IL-17 Inhibitors for Psoriasis sales for 2026 through 2032. With IL-17 Inhibitors for Psoriasis sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world IL-17 Inhibitors for Psoriasis industry.
This Insight Report provides a comprehensive analysis of the global IL-17 Inhibitors for Psoriasis landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on IL-17 Inhibitors for Psoriasis portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global IL-17 Inhibitors for Psoriasis market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for IL-17 Inhibitors for Psoriasis and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global IL-17 Inhibitors for Psoriasis.
This report presents a comprehensive overview, market shares, and growth opportunities of IL-17 Inhibitors for Psoriasis market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global IL-17 Inhibitors for Psoriasis market?
What factors are driving IL-17 Inhibitors for Psoriasis market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do IL-17 Inhibitors for Psoriasis market opportunities vary by end market size?
How does IL-17 Inhibitors for Psoriasis break out by Type, by Application?
IL-17 inhibitors for psoriasis are a class of biologic drugs designed to target and block the activity of interleukin-17 (IL-17), a pro-inflammatory cytokine that plays a critical role in the pathogenesis of psoriasis. By inhibiting IL-17, these drugs reduce the excessive immune response and help control the symptoms of moderate to severe plaque psoriasis. Examples of IL-17 inhibitors include secukinumab, ixekizumab, brodalumab and so on.
United States market for IL-17 Inhibitors for Psoriasis is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for IL-17 Inhibitors for Psoriasis is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for IL-17 Inhibitors for Psoriasis is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key IL-17 Inhibitors for Psoriasis players cover UCB, Eli Lilly, Novartis, Ortho Dermatologics, LEO Pharma, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the ?IL-17 Inhibitors for Psoriasis Industry Forecast? looks at past sales and reviews total world IL-17 Inhibitors for Psoriasis sales in 2025, providing a comprehensive analysis by region and market sector of projected IL-17 Inhibitors for Psoriasis sales for 2026 through 2032. With IL-17 Inhibitors for Psoriasis sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world IL-17 Inhibitors for Psoriasis industry.
This Insight Report provides a comprehensive analysis of the global IL-17 Inhibitors for Psoriasis landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on IL-17 Inhibitors for Psoriasis portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global IL-17 Inhibitors for Psoriasis market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for IL-17 Inhibitors for Psoriasis and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global IL-17 Inhibitors for Psoriasis.
This report presents a comprehensive overview, market shares, and growth opportunities of IL-17 Inhibitors for Psoriasis market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Bimelizumab
- Secukinumab
- Ixekizumab
- Brodalumab
- Vunakizumab
- Xeligekimab
- Other
- Hospital and Clinic
- Pharmacy
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- UCB
- Eli Lilly
- Novartis
- Ortho Dermatologics
- LEO Pharma
- Kyowa Kirin
- Jiangsu Hengrui Pharmaceuticals
- Chongqing Genrix Biopharmaceutical
What is the 10-year outlook for the global IL-17 Inhibitors for Psoriasis market?
What factors are driving IL-17 Inhibitors for Psoriasis market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do IL-17 Inhibitors for Psoriasis market opportunities vary by end market size?
How does IL-17 Inhibitors for Psoriasis break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global IL-17 Inhibitors for Psoriasis Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for IL-17 Inhibitors for Psoriasis by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for IL-17 Inhibitors for Psoriasis by Country/Region, 2021, 2025 & 2032
2.2 IL-17 Inhibitors for Psoriasis Segment by Type
2.2.1 Bimelizumab
2.2.2 Secukinumab
2.2.3 Ixekizumab
2.2.4 Brodalumab
2.2.5 Vunakizumab
2.2.6 Xeligekimab
2.2.7 Other
2.2.8 IL-17 Inhibitors for Psoriasis Sales by Type
2.2.8.1 Global IL-17 Inhibitors for Psoriasis Sales Market Share by Type (2021-2026)
2.2.8.2 Global IL-17 Inhibitors for Psoriasis Revenue and Market Share by Type (2021-2026)
2.2.8.3 Global IL-17 Inhibitors for Psoriasis Sale Price by Type (2021-2026)
2.3 IL-17 Inhibitors for Psoriasis Segment by Application
2.3.1 Hospital and Clinic
2.3.2 Pharmacy
2.3.3 Other
2.3.4 IL-17 Inhibitors for Psoriasis Sales by Application
2.3.4.1 Global IL-17 Inhibitors for Psoriasis Sale Market Share by Application (2021-2026)
2.3.4.2 Global IL-17 Inhibitors for Psoriasis Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global IL-17 Inhibitors for Psoriasis Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global IL-17 Inhibitors for Psoriasis Breakdown Data by Company
3.1.1 Global IL-17 Inhibitors for Psoriasis Annual Sales by Company (2021-2026)
3.1.2 Global IL-17 Inhibitors for Psoriasis Sales Market Share by Company (2021-2026)
3.2 Global IL-17 Inhibitors for Psoriasis Annual Revenue by Company (2021-2026)
3.2.1 Global IL-17 Inhibitors for Psoriasis Revenue by Company (2021-2026)
3.2.2 Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Company (2021-2026)
3.3 Global IL-17 Inhibitors for Psoriasis Sale Price by Company
3.4 Key Manufacturers IL-17 Inhibitors for Psoriasis Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers IL-17 Inhibitors for Psoriasis Product Location Distribution
3.4.2 Players IL-17 Inhibitors for Psoriasis Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR IL-17 INHIBITORS FOR PSORIASIS BY GEOGRAPHIC REGION
4.1 World Historic IL-17 Inhibitors for Psoriasis Market Size by Geographic Region (2021-2026)
4.1.1 Global IL-17 Inhibitors for Psoriasis Annual Sales by Geographic Region (2021-2026)
4.1.2 Global IL-17 Inhibitors for Psoriasis Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic IL-17 Inhibitors for Psoriasis Market Size by Country/Region (2021-2026)
4.2.1 Global IL-17 Inhibitors for Psoriasis Annual Sales by Country/Region (2021-2026)
4.2.2 Global IL-17 Inhibitors for Psoriasis Annual Revenue by Country/Region (2021-2026)
4.3 Americas IL-17 Inhibitors for Psoriasis Sales Growth
4.4 APAC IL-17 Inhibitors for Psoriasis Sales Growth
4.5 Europe IL-17 Inhibitors for Psoriasis Sales Growth
4.6 Middle East & Africa IL-17 Inhibitors for Psoriasis Sales Growth
5 AMERICAS
5.1 Americas IL-17 Inhibitors for Psoriasis Sales by Country
5.1.1 Americas IL-17 Inhibitors for Psoriasis Sales by Country (2021-2026)
5.1.2 Americas IL-17 Inhibitors for Psoriasis Revenue by Country (2021-2026)
5.2 Americas IL-17 Inhibitors for Psoriasis Sales by Type (2021-2026)
5.3 Americas IL-17 Inhibitors for Psoriasis Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC IL-17 Inhibitors for Psoriasis Sales by Region
6.1.1 APAC IL-17 Inhibitors for Psoriasis Sales by Region (2021-2026)
6.1.2 APAC IL-17 Inhibitors for Psoriasis Revenue by Region (2021-2026)
6.2 APAC IL-17 Inhibitors for Psoriasis Sales by Type (2021-2026)
6.3 APAC IL-17 Inhibitors for Psoriasis Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe IL-17 Inhibitors for Psoriasis by Country
7.1.1 Europe IL-17 Inhibitors for Psoriasis Sales by Country (2021-2026)
7.1.2 Europe IL-17 Inhibitors for Psoriasis Revenue by Country (2021-2026)
7.2 Europe IL-17 Inhibitors for Psoriasis Sales by Type (2021-2026)
7.3 Europe IL-17 Inhibitors for Psoriasis Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa IL-17 Inhibitors for Psoriasis by Country
8.1.1 Middle East & Africa IL-17 Inhibitors for Psoriasis Sales by Country (2021-2026)
8.1.2 Middle East & Africa IL-17 Inhibitors for Psoriasis Revenue by Country (2021-2026)
8.2 Middle East & Africa IL-17 Inhibitors for Psoriasis Sales by Type (2021-2026)
8.3 Middle East & Africa IL-17 Inhibitors for Psoriasis Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of IL-17 Inhibitors for Psoriasis
10.3 Manufacturing Process Analysis of IL-17 Inhibitors for Psoriasis
10.4 Industry Chain Structure of IL-17 Inhibitors for Psoriasis
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 IL-17 Inhibitors for Psoriasis Distributors
11.3 IL-17 Inhibitors for Psoriasis Customer
12 WORLD FORECAST REVIEW FOR IL-17 INHIBITORS FOR PSORIASIS BY GEOGRAPHIC REGION
12.1 Global IL-17 Inhibitors for Psoriasis Market Size Forecast by Region
12.1.1 Global IL-17 Inhibitors for Psoriasis Forecast by Region (2027-2032)
12.1.2 Global IL-17 Inhibitors for Psoriasis Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global IL-17 Inhibitors for Psoriasis Forecast by Type (2027-2032)
12.7 Global IL-17 Inhibitors for Psoriasis Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 UCB
13.1.1 UCB Company Information
13.1.2 UCB IL-17 Inhibitors for Psoriasis Product Portfolios and Specifications
13.1.3 UCB IL-17 Inhibitors for Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 UCB Main Business Overview
13.1.5 UCB Latest Developments
13.2 Eli Lilly
13.2.1 Eli Lilly Company Information
13.2.2 Eli Lilly IL-17 Inhibitors for Psoriasis Product Portfolios and Specifications
13.2.3 Eli Lilly IL-17 Inhibitors for Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Eli Lilly Main Business Overview
13.2.5 Eli Lilly Latest Developments
13.3 Novartis
13.3.1 Novartis Company Information
13.3.2 Novartis IL-17 Inhibitors for Psoriasis Product Portfolios and Specifications
13.3.3 Novartis IL-17 Inhibitors for Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Novartis Main Business Overview
13.3.5 Novartis Latest Developments
13.4 Ortho Dermatologics
13.4.1 Ortho Dermatologics Company Information
13.4.2 Ortho Dermatologics IL-17 Inhibitors for Psoriasis Product Portfolios and Specifications
13.4.3 Ortho Dermatologics IL-17 Inhibitors for Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Ortho Dermatologics Main Business Overview
13.4.5 Ortho Dermatologics Latest Developments
13.5 LEO Pharma
13.5.1 LEO Pharma Company Information
13.5.2 LEO Pharma IL-17 Inhibitors for Psoriasis Product Portfolios and Specifications
13.5.3 LEO Pharma IL-17 Inhibitors for Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 LEO Pharma Main Business Overview
13.5.5 LEO Pharma Latest Developments
13.6 Kyowa Kirin
13.6.1 Kyowa Kirin Company Information
13.6.2 Kyowa Kirin IL-17 Inhibitors for Psoriasis Product Portfolios and Specifications
13.6.3 Kyowa Kirin IL-17 Inhibitors for Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Kyowa Kirin Main Business Overview
13.6.5 Kyowa Kirin Latest Developments
13.7 Jiangsu Hengrui Pharmaceuticals
13.7.1 Jiangsu Hengrui Pharmaceuticals Company Information
13.7.2 Jiangsu Hengrui Pharmaceuticals IL-17 Inhibitors for Psoriasis Product Portfolios and Specifications
13.7.3 Jiangsu Hengrui Pharmaceuticals IL-17 Inhibitors for Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Jiangsu Hengrui Pharmaceuticals Main Business Overview
13.7.5 Jiangsu Hengrui Pharmaceuticals Latest Developments
13.8 Chongqing Genrix Biopharmaceutical
13.8.1 Chongqing Genrix Biopharmaceutical Company Information
13.8.2 Chongqing Genrix Biopharmaceutical IL-17 Inhibitors for Psoriasis Product Portfolios and Specifications
13.8.3 Chongqing Genrix Biopharmaceutical IL-17 Inhibitors for Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Chongqing Genrix Biopharmaceutical Main Business Overview
13.8.5 Chongqing Genrix Biopharmaceutical Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global IL-17 Inhibitors for Psoriasis Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for IL-17 Inhibitors for Psoriasis by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for IL-17 Inhibitors for Psoriasis by Country/Region, 2021, 2025 & 2032
2.2 IL-17 Inhibitors for Psoriasis Segment by Type
2.2.1 Bimelizumab
2.2.2 Secukinumab
2.2.3 Ixekizumab
2.2.4 Brodalumab
2.2.5 Vunakizumab
2.2.6 Xeligekimab
2.2.7 Other
2.2.8 IL-17 Inhibitors for Psoriasis Sales by Type
2.2.8.1 Global IL-17 Inhibitors for Psoriasis Sales Market Share by Type (2021-2026)
2.2.8.2 Global IL-17 Inhibitors for Psoriasis Revenue and Market Share by Type (2021-2026)
2.2.8.3 Global IL-17 Inhibitors for Psoriasis Sale Price by Type (2021-2026)
2.3 IL-17 Inhibitors for Psoriasis Segment by Application
2.3.1 Hospital and Clinic
2.3.2 Pharmacy
2.3.3 Other
2.3.4 IL-17 Inhibitors for Psoriasis Sales by Application
2.3.4.1 Global IL-17 Inhibitors for Psoriasis Sale Market Share by Application (2021-2026)
2.3.4.2 Global IL-17 Inhibitors for Psoriasis Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global IL-17 Inhibitors for Psoriasis Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global IL-17 Inhibitors for Psoriasis Breakdown Data by Company
3.1.1 Global IL-17 Inhibitors for Psoriasis Annual Sales by Company (2021-2026)
3.1.2 Global IL-17 Inhibitors for Psoriasis Sales Market Share by Company (2021-2026)
3.2 Global IL-17 Inhibitors for Psoriasis Annual Revenue by Company (2021-2026)
3.2.1 Global IL-17 Inhibitors for Psoriasis Revenue by Company (2021-2026)
3.2.2 Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Company (2021-2026)
3.3 Global IL-17 Inhibitors for Psoriasis Sale Price by Company
3.4 Key Manufacturers IL-17 Inhibitors for Psoriasis Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers IL-17 Inhibitors for Psoriasis Product Location Distribution
3.4.2 Players IL-17 Inhibitors for Psoriasis Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR IL-17 INHIBITORS FOR PSORIASIS BY GEOGRAPHIC REGION
4.1 World Historic IL-17 Inhibitors for Psoriasis Market Size by Geographic Region (2021-2026)
4.1.1 Global IL-17 Inhibitors for Psoriasis Annual Sales by Geographic Region (2021-2026)
4.1.2 Global IL-17 Inhibitors for Psoriasis Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic IL-17 Inhibitors for Psoriasis Market Size by Country/Region (2021-2026)
4.2.1 Global IL-17 Inhibitors for Psoriasis Annual Sales by Country/Region (2021-2026)
4.2.2 Global IL-17 Inhibitors for Psoriasis Annual Revenue by Country/Region (2021-2026)
4.3 Americas IL-17 Inhibitors for Psoriasis Sales Growth
4.4 APAC IL-17 Inhibitors for Psoriasis Sales Growth
4.5 Europe IL-17 Inhibitors for Psoriasis Sales Growth
4.6 Middle East & Africa IL-17 Inhibitors for Psoriasis Sales Growth
5 AMERICAS
5.1 Americas IL-17 Inhibitors for Psoriasis Sales by Country
5.1.1 Americas IL-17 Inhibitors for Psoriasis Sales by Country (2021-2026)
5.1.2 Americas IL-17 Inhibitors for Psoriasis Revenue by Country (2021-2026)
5.2 Americas IL-17 Inhibitors for Psoriasis Sales by Type (2021-2026)
5.3 Americas IL-17 Inhibitors for Psoriasis Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC IL-17 Inhibitors for Psoriasis Sales by Region
6.1.1 APAC IL-17 Inhibitors for Psoriasis Sales by Region (2021-2026)
6.1.2 APAC IL-17 Inhibitors for Psoriasis Revenue by Region (2021-2026)
6.2 APAC IL-17 Inhibitors for Psoriasis Sales by Type (2021-2026)
6.3 APAC IL-17 Inhibitors for Psoriasis Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe IL-17 Inhibitors for Psoriasis by Country
7.1.1 Europe IL-17 Inhibitors for Psoriasis Sales by Country (2021-2026)
7.1.2 Europe IL-17 Inhibitors for Psoriasis Revenue by Country (2021-2026)
7.2 Europe IL-17 Inhibitors for Psoriasis Sales by Type (2021-2026)
7.3 Europe IL-17 Inhibitors for Psoriasis Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa IL-17 Inhibitors for Psoriasis by Country
8.1.1 Middle East & Africa IL-17 Inhibitors for Psoriasis Sales by Country (2021-2026)
8.1.2 Middle East & Africa IL-17 Inhibitors for Psoriasis Revenue by Country (2021-2026)
8.2 Middle East & Africa IL-17 Inhibitors for Psoriasis Sales by Type (2021-2026)
8.3 Middle East & Africa IL-17 Inhibitors for Psoriasis Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of IL-17 Inhibitors for Psoriasis
10.3 Manufacturing Process Analysis of IL-17 Inhibitors for Psoriasis
10.4 Industry Chain Structure of IL-17 Inhibitors for Psoriasis
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 IL-17 Inhibitors for Psoriasis Distributors
11.3 IL-17 Inhibitors for Psoriasis Customer
12 WORLD FORECAST REVIEW FOR IL-17 INHIBITORS FOR PSORIASIS BY GEOGRAPHIC REGION
12.1 Global IL-17 Inhibitors for Psoriasis Market Size Forecast by Region
12.1.1 Global IL-17 Inhibitors for Psoriasis Forecast by Region (2027-2032)
12.1.2 Global IL-17 Inhibitors for Psoriasis Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global IL-17 Inhibitors for Psoriasis Forecast by Type (2027-2032)
12.7 Global IL-17 Inhibitors for Psoriasis Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 UCB
13.1.1 UCB Company Information
13.1.2 UCB IL-17 Inhibitors for Psoriasis Product Portfolios and Specifications
13.1.3 UCB IL-17 Inhibitors for Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 UCB Main Business Overview
13.1.5 UCB Latest Developments
13.2 Eli Lilly
13.2.1 Eli Lilly Company Information
13.2.2 Eli Lilly IL-17 Inhibitors for Psoriasis Product Portfolios and Specifications
13.2.3 Eli Lilly IL-17 Inhibitors for Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Eli Lilly Main Business Overview
13.2.5 Eli Lilly Latest Developments
13.3 Novartis
13.3.1 Novartis Company Information
13.3.2 Novartis IL-17 Inhibitors for Psoriasis Product Portfolios and Specifications
13.3.3 Novartis IL-17 Inhibitors for Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Novartis Main Business Overview
13.3.5 Novartis Latest Developments
13.4 Ortho Dermatologics
13.4.1 Ortho Dermatologics Company Information
13.4.2 Ortho Dermatologics IL-17 Inhibitors for Psoriasis Product Portfolios and Specifications
13.4.3 Ortho Dermatologics IL-17 Inhibitors for Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Ortho Dermatologics Main Business Overview
13.4.5 Ortho Dermatologics Latest Developments
13.5 LEO Pharma
13.5.1 LEO Pharma Company Information
13.5.2 LEO Pharma IL-17 Inhibitors for Psoriasis Product Portfolios and Specifications
13.5.3 LEO Pharma IL-17 Inhibitors for Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 LEO Pharma Main Business Overview
13.5.5 LEO Pharma Latest Developments
13.6 Kyowa Kirin
13.6.1 Kyowa Kirin Company Information
13.6.2 Kyowa Kirin IL-17 Inhibitors for Psoriasis Product Portfolios and Specifications
13.6.3 Kyowa Kirin IL-17 Inhibitors for Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Kyowa Kirin Main Business Overview
13.6.5 Kyowa Kirin Latest Developments
13.7 Jiangsu Hengrui Pharmaceuticals
13.7.1 Jiangsu Hengrui Pharmaceuticals Company Information
13.7.2 Jiangsu Hengrui Pharmaceuticals IL-17 Inhibitors for Psoriasis Product Portfolios and Specifications
13.7.3 Jiangsu Hengrui Pharmaceuticals IL-17 Inhibitors for Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Jiangsu Hengrui Pharmaceuticals Main Business Overview
13.7.5 Jiangsu Hengrui Pharmaceuticals Latest Developments
13.8 Chongqing Genrix Biopharmaceutical
13.8.1 Chongqing Genrix Biopharmaceutical Company Information
13.8.2 Chongqing Genrix Biopharmaceutical IL-17 Inhibitors for Psoriasis Product Portfolios and Specifications
13.8.3 Chongqing Genrix Biopharmaceutical IL-17 Inhibitors for Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Chongqing Genrix Biopharmaceutical Main Business Overview
13.8.5 Chongqing Genrix Biopharmaceutical Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. IL-17 Inhibitors for Psoriasis Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. IL-17 Inhibitors for Psoriasis Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Bimelizumab
Table 4. Major Players of Secukinumab
Table 5. Major Players of Ixekizumab
Table 6. Major Players of Brodalumab
Table 7. Major Players of Vunakizumab
Table 8. Major Players of Xeligekimab
Table 9. Major Players of Other
Table 10. Global IL-17 Inhibitors for Psoriasis Sales by Type (2021-2026) & (K Units)
Table 11. Global IL-17 Inhibitors for Psoriasis Sales Market Share by Type (2021-2026)
Table 12. Global IL-17 Inhibitors for Psoriasis Revenue by Type (2021-2026) & ($ million)
Table 13. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Type (2021-2026)
Table 14. Global IL-17 Inhibitors for Psoriasis Sale Price by Type (2021-2026) & (US$/Unit)
Table 15. Global IL-17 Inhibitors for Psoriasis Sale by Application (2021-2026) & (K Units)
Table 16. Global IL-17 Inhibitors for Psoriasis Sale Market Share by Application (2021-2026)
Table 17. Global IL-17 Inhibitors for Psoriasis Revenue by Application (2021-2026) & ($ million)
Table 18. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Application (2021-2026)
Table 19. Global IL-17 Inhibitors for Psoriasis Sale Price by Application (2021-2026) & (US$/Unit)
Table 20. Global IL-17 Inhibitors for Psoriasis Sales by Company (2021-2026) & (K Units)
Table 21. Global IL-17 Inhibitors for Psoriasis Sales Market Share by Company (2021-2026)
Table 22. Global IL-17 Inhibitors for Psoriasis Revenue by Company (2021-2026) & ($ millions)
Table 23. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Company (2021-2026)
Table 24. Global IL-17 Inhibitors for Psoriasis Sale Price by Company (2021-2026) & (US$/Unit)
Table 25. Key Manufacturers IL-17 Inhibitors for Psoriasis Producing Area Distribution and Sales Area
Table 26. Players IL-17 Inhibitors for Psoriasis Products Offered
Table 27. IL-17 Inhibitors for Psoriasis Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 28. New Products and Potential Entrants
Table 29. Market M&A Activity & Strategy
Table 30. Global IL-17 Inhibitors for Psoriasis Sales by Geographic Region (2021-2026) & (K Units)
Table 31. Global IL-17 Inhibitors for Psoriasis Sales Market Share Geographic Region (2021-2026)
Table 32. Global IL-17 Inhibitors for Psoriasis Revenue by Geographic Region (2021-2026) & ($ millions)
Table 33. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Geographic Region (2021-2026)
Table 34. Global IL-17 Inhibitors for Psoriasis Sales by Country/Region (2021-2026) & (K Units)
Table 35. Global IL-17 Inhibitors for Psoriasis Sales Market Share by Country/Region (2021-2026)
Table 36. Global IL-17 Inhibitors for Psoriasis Revenue by Country/Region (2021-2026) & ($ millions)
Table 37. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Country/Region (2021-2026)
Table 38. Americas IL-17 Inhibitors for Psoriasis Sales by Country (2021-2026) & (K Units)
Table 39. Americas IL-17 Inhibitors for Psoriasis Sales Market Share by Country (2021-2026)
Table 40. Americas IL-17 Inhibitors for Psoriasis Revenue by Country (2021-2026) & ($ millions)
Table 41. Americas IL-17 Inhibitors for Psoriasis Sales by Type (2021-2026) & (K Units)
Table 42. Americas IL-17 Inhibitors for Psoriasis Sales by Application (2021-2026) & (K Units)
Table 43. APAC IL-17 Inhibitors for Psoriasis Sales by Region (2021-2026) & (K Units)
Table 44. APAC IL-17 Inhibitors for Psoriasis Sales Market Share by Region (2021-2026)
Table 45. APAC IL-17 Inhibitors for Psoriasis Revenue by Region (2021-2026) & ($ millions)
Table 46. APAC IL-17 Inhibitors for Psoriasis Sales by Type (2021-2026) & (K Units)
Table 47. APAC IL-17 Inhibitors for Psoriasis Sales by Application (2021-2026) & (K Units)
Table 48. Europe IL-17 Inhibitors for Psoriasis Sales by Country (2021-2026) & (K Units)
Table 49. Europe IL-17 Inhibitors for Psoriasis Revenue by Country (2021-2026) & ($ millions)
Table 50. Europe IL-17 Inhibitors for Psoriasis Sales by Type (2021-2026) & (K Units)
Table 51. Europe IL-17 Inhibitors for Psoriasis Sales by Application (2021-2026) & (K Units)
Table 52. Middle East & Africa IL-17 Inhibitors for Psoriasis Sales by Country (2021-2026) & (K Units)
Table 53. Middle East & Africa IL-17 Inhibitors for Psoriasis Revenue Market Share by Country (2021-2026)
Table 54. Middle East & Africa IL-17 Inhibitors for Psoriasis Sales by Type (2021-2026) & (K Units)
Table 55. Middle East & Africa IL-17 Inhibitors for Psoriasis Sales by Application (2021-2026) & (K Units)
Table 56. Key Market Drivers & Growth Opportunities of IL-17 Inhibitors for Psoriasis
Table 57. Key Market Challenges & Risks of IL-17 Inhibitors for Psoriasis
Table 58. Key Industry Trends of IL-17 Inhibitors for Psoriasis
Table 59. IL-17 Inhibitors for Psoriasis Raw Material
Table 60. Key Suppliers of Raw Materials
Table 61. IL-17 Inhibitors for Psoriasis Distributors List
Table 62. IL-17 Inhibitors for Psoriasis Customer List
Table 63. Global IL-17 Inhibitors for Psoriasis Sales Forecast by Region (2027-2032) & (K Units)
Table 64. Global IL-17 Inhibitors for Psoriasis Revenue Forecast by Region (2027-2032) & ($ millions)
Table 65. Americas IL-17 Inhibitors for Psoriasis Sales Forecast by Country (2027-2032) & (K Units)
Table 66. Americas IL-17 Inhibitors for Psoriasis Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 67. APAC IL-17 Inhibitors for Psoriasis Sales Forecast by Region (2027-2032) & (K Units)
Table 68. APAC IL-17 Inhibitors for Psoriasis Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 69. Europe IL-17 Inhibitors for Psoriasis Sales Forecast by Country (2027-2032) & (K Units)
Table 70. Europe IL-17 Inhibitors for Psoriasis Revenue Forecast by Country (2027-2032) & ($ millions)
Table 71. Middle East & Africa IL-17 Inhibitors for Psoriasis Sales Forecast by Country (2027-2032) & (K Units)
Table 72. Middle East & Africa IL-17 Inhibitors for Psoriasis Revenue Forecast by Country (2027-2032) & ($ millions)
Table 73. Global IL-17 Inhibitors for Psoriasis Sales Forecast by Type (2027-2032) & (K Units)
Table 74. Global IL-17 Inhibitors for Psoriasis Revenue Forecast by Type (2027-2032) & ($ millions)
Table 75. Global IL-17 Inhibitors for Psoriasis Sales Forecast by Application (2027-2032) & (K Units)
Table 76. Global IL-17 Inhibitors for Psoriasis Revenue Forecast by Application (2027-2032) & ($ millions)
Table 77. UCB Basic Information, IL-17 Inhibitors for Psoriasis Manufacturing Base, Sales Area and Its Competitors
Table 78. UCB IL-17 Inhibitors for Psoriasis Product Portfolios and Specifications
Table 79. UCB IL-17 Inhibitors for Psoriasis Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 80. UCB Main Business
Table 81. UCB Latest Developments
Table 82. Eli Lilly Basic Information, IL-17 Inhibitors for Psoriasis Manufacturing Base, Sales Area and Its Competitors
Table 83. Eli Lilly IL-17 Inhibitors for Psoriasis Product Portfolios and Specifications
Table 84. Eli Lilly IL-17 Inhibitors for Psoriasis Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 85. Eli Lilly Main Business
Table 86. Eli Lilly Latest Developments
Table 87. Novartis Basic Information, IL-17 Inhibitors for Psoriasis Manufacturing Base, Sales Area and Its Competitors
Table 88. Novartis IL-17 Inhibitors for Psoriasis Product Portfolios and Specifications
Table 89. Novartis IL-17 Inhibitors for Psoriasis Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 90. Novartis Main Business
Table 91. Novartis Latest Developments
Table 92. Ortho Dermatologics Basic Information, IL-17 Inhibitors for Psoriasis Manufacturing Base, Sales Area and Its Competitors
Table 93. Ortho Dermatologics IL-17 Inhibitors for Psoriasis Product Portfolios and Specifications
Table 94. Ortho Dermatologics IL-17 Inhibitors for Psoriasis Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 95. Ortho Dermatologics Main Business
Table 96. Ortho Dermatologics Latest Developments
Table 97. LEO Pharma Basic Information, IL-17 Inhibitors for Psoriasis Manufacturing Base, Sales Area and Its Competitors
Table 98. LEO Pharma IL-17 Inhibitors for Psoriasis Product Portfolios and Specifications
Table 99. LEO Pharma IL-17 Inhibitors for Psoriasis Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 100. LEO Pharma Main Business
Table 101. LEO Pharma Latest Developments
Table 102. Kyowa Kirin Basic Information, IL-17 Inhibitors for Psoriasis Manufacturing Base, Sales Area and Its Competitors
Table 103. Kyowa Kirin IL-17 Inhibitors for Psoriasis Product Portfolios and Specifications
Table 104. Kyowa Kirin IL-17 Inhibitors for Psoriasis Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 105. Kyowa Kirin Main Business
Table 106. Kyowa Kirin Latest Developments
Table 107. Jiangsu Hengrui Pharmaceuticals Basic Information, IL-17 Inhibitors for Psoriasis Manufacturing Base, Sales Area and Its Competitors
Table 108. Jiangsu Hengrui Pharmaceuticals IL-17 Inhibitors for Psoriasis Product Portfolios and Specifications
Table 109. Jiangsu Hengrui Pharmaceuticals IL-17 Inhibitors for Psoriasis Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 110. Jiangsu Hengrui Pharmaceuticals Main Business
Table 111. Jiangsu Hengrui Pharmaceuticals Latest Developments
Table 112. Chongqing Genrix Biopharmaceutical Basic Information, IL-17 Inhibitors for Psoriasis Manufacturing Base, Sales Area and Its Competitors
Table 113. Chongqing Genrix Biopharmaceutical IL-17 Inhibitors for Psoriasis Product Portfolios and Specifications
Table 114. Chongqing Genrix Biopharmaceutical IL-17 Inhibitors for Psoriasis Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 115. Chongqing Genrix Biopharmaceutical Main Business
Table 116. Chongqing Genrix Biopharmaceutical Latest Developments
Table 1. IL-17 Inhibitors for Psoriasis Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. IL-17 Inhibitors for Psoriasis Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Bimelizumab
Table 4. Major Players of Secukinumab
Table 5. Major Players of Ixekizumab
Table 6. Major Players of Brodalumab
Table 7. Major Players of Vunakizumab
Table 8. Major Players of Xeligekimab
Table 9. Major Players of Other
Table 10. Global IL-17 Inhibitors for Psoriasis Sales by Type (2021-2026) & (K Units)
Table 11. Global IL-17 Inhibitors for Psoriasis Sales Market Share by Type (2021-2026)
Table 12. Global IL-17 Inhibitors for Psoriasis Revenue by Type (2021-2026) & ($ million)
Table 13. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Type (2021-2026)
Table 14. Global IL-17 Inhibitors for Psoriasis Sale Price by Type (2021-2026) & (US$/Unit)
Table 15. Global IL-17 Inhibitors for Psoriasis Sale by Application (2021-2026) & (K Units)
Table 16. Global IL-17 Inhibitors for Psoriasis Sale Market Share by Application (2021-2026)
Table 17. Global IL-17 Inhibitors for Psoriasis Revenue by Application (2021-2026) & ($ million)
Table 18. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Application (2021-2026)
Table 19. Global IL-17 Inhibitors for Psoriasis Sale Price by Application (2021-2026) & (US$/Unit)
Table 20. Global IL-17 Inhibitors for Psoriasis Sales by Company (2021-2026) & (K Units)
Table 21. Global IL-17 Inhibitors for Psoriasis Sales Market Share by Company (2021-2026)
Table 22. Global IL-17 Inhibitors for Psoriasis Revenue by Company (2021-2026) & ($ millions)
Table 23. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Company (2021-2026)
Table 24. Global IL-17 Inhibitors for Psoriasis Sale Price by Company (2021-2026) & (US$/Unit)
Table 25. Key Manufacturers IL-17 Inhibitors for Psoriasis Producing Area Distribution and Sales Area
Table 26. Players IL-17 Inhibitors for Psoriasis Products Offered
Table 27. IL-17 Inhibitors for Psoriasis Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 28. New Products and Potential Entrants
Table 29. Market M&A Activity & Strategy
Table 30. Global IL-17 Inhibitors for Psoriasis Sales by Geographic Region (2021-2026) & (K Units)
Table 31. Global IL-17 Inhibitors for Psoriasis Sales Market Share Geographic Region (2021-2026)
Table 32. Global IL-17 Inhibitors for Psoriasis Revenue by Geographic Region (2021-2026) & ($ millions)
Table 33. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Geographic Region (2021-2026)
Table 34. Global IL-17 Inhibitors for Psoriasis Sales by Country/Region (2021-2026) & (K Units)
Table 35. Global IL-17 Inhibitors for Psoriasis Sales Market Share by Country/Region (2021-2026)
Table 36. Global IL-17 Inhibitors for Psoriasis Revenue by Country/Region (2021-2026) & ($ millions)
Table 37. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Country/Region (2021-2026)
Table 38. Americas IL-17 Inhibitors for Psoriasis Sales by Country (2021-2026) & (K Units)
Table 39. Americas IL-17 Inhibitors for Psoriasis Sales Market Share by Country (2021-2026)
Table 40. Americas IL-17 Inhibitors for Psoriasis Revenue by Country (2021-2026) & ($ millions)
Table 41. Americas IL-17 Inhibitors for Psoriasis Sales by Type (2021-2026) & (K Units)
Table 42. Americas IL-17 Inhibitors for Psoriasis Sales by Application (2021-2026) & (K Units)
Table 43. APAC IL-17 Inhibitors for Psoriasis Sales by Region (2021-2026) & (K Units)
Table 44. APAC IL-17 Inhibitors for Psoriasis Sales Market Share by Region (2021-2026)
Table 45. APAC IL-17 Inhibitors for Psoriasis Revenue by Region (2021-2026) & ($ millions)
Table 46. APAC IL-17 Inhibitors for Psoriasis Sales by Type (2021-2026) & (K Units)
Table 47. APAC IL-17 Inhibitors for Psoriasis Sales by Application (2021-2026) & (K Units)
Table 48. Europe IL-17 Inhibitors for Psoriasis Sales by Country (2021-2026) & (K Units)
Table 49. Europe IL-17 Inhibitors for Psoriasis Revenue by Country (2021-2026) & ($ millions)
Table 50. Europe IL-17 Inhibitors for Psoriasis Sales by Type (2021-2026) & (K Units)
Table 51. Europe IL-17 Inhibitors for Psoriasis Sales by Application (2021-2026) & (K Units)
Table 52. Middle East & Africa IL-17 Inhibitors for Psoriasis Sales by Country (2021-2026) & (K Units)
Table 53. Middle East & Africa IL-17 Inhibitors for Psoriasis Revenue Market Share by Country (2021-2026)
Table 54. Middle East & Africa IL-17 Inhibitors for Psoriasis Sales by Type (2021-2026) & (K Units)
Table 55. Middle East & Africa IL-17 Inhibitors for Psoriasis Sales by Application (2021-2026) & (K Units)
Table 56. Key Market Drivers & Growth Opportunities of IL-17 Inhibitors for Psoriasis
Table 57. Key Market Challenges & Risks of IL-17 Inhibitors for Psoriasis
Table 58. Key Industry Trends of IL-17 Inhibitors for Psoriasis
Table 59. IL-17 Inhibitors for Psoriasis Raw Material
Table 60. Key Suppliers of Raw Materials
Table 61. IL-17 Inhibitors for Psoriasis Distributors List
Table 62. IL-17 Inhibitors for Psoriasis Customer List
Table 63. Global IL-17 Inhibitors for Psoriasis Sales Forecast by Region (2027-2032) & (K Units)
Table 64. Global IL-17 Inhibitors for Psoriasis Revenue Forecast by Region (2027-2032) & ($ millions)
Table 65. Americas IL-17 Inhibitors for Psoriasis Sales Forecast by Country (2027-2032) & (K Units)
Table 66. Americas IL-17 Inhibitors for Psoriasis Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 67. APAC IL-17 Inhibitors for Psoriasis Sales Forecast by Region (2027-2032) & (K Units)
Table 68. APAC IL-17 Inhibitors for Psoriasis Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 69. Europe IL-17 Inhibitors for Psoriasis Sales Forecast by Country (2027-2032) & (K Units)
Table 70. Europe IL-17 Inhibitors for Psoriasis Revenue Forecast by Country (2027-2032) & ($ millions)
Table 71. Middle East & Africa IL-17 Inhibitors for Psoriasis Sales Forecast by Country (2027-2032) & (K Units)
Table 72. Middle East & Africa IL-17 Inhibitors for Psoriasis Revenue Forecast by Country (2027-2032) & ($ millions)
Table 73. Global IL-17 Inhibitors for Psoriasis Sales Forecast by Type (2027-2032) & (K Units)
Table 74. Global IL-17 Inhibitors for Psoriasis Revenue Forecast by Type (2027-2032) & ($ millions)
Table 75. Global IL-17 Inhibitors for Psoriasis Sales Forecast by Application (2027-2032) & (K Units)
Table 76. Global IL-17 Inhibitors for Psoriasis Revenue Forecast by Application (2027-2032) & ($ millions)
Table 77. UCB Basic Information, IL-17 Inhibitors for Psoriasis Manufacturing Base, Sales Area and Its Competitors
Table 78. UCB IL-17 Inhibitors for Psoriasis Product Portfolios and Specifications
Table 79. UCB IL-17 Inhibitors for Psoriasis Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 80. UCB Main Business
Table 81. UCB Latest Developments
Table 82. Eli Lilly Basic Information, IL-17 Inhibitors for Psoriasis Manufacturing Base, Sales Area and Its Competitors
Table 83. Eli Lilly IL-17 Inhibitors for Psoriasis Product Portfolios and Specifications
Table 84. Eli Lilly IL-17 Inhibitors for Psoriasis Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 85. Eli Lilly Main Business
Table 86. Eli Lilly Latest Developments
Table 87. Novartis Basic Information, IL-17 Inhibitors for Psoriasis Manufacturing Base, Sales Area and Its Competitors
Table 88. Novartis IL-17 Inhibitors for Psoriasis Product Portfolios and Specifications
Table 89. Novartis IL-17 Inhibitors for Psoriasis Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 90. Novartis Main Business
Table 91. Novartis Latest Developments
Table 92. Ortho Dermatologics Basic Information, IL-17 Inhibitors for Psoriasis Manufacturing Base, Sales Area and Its Competitors
Table 93. Ortho Dermatologics IL-17 Inhibitors for Psoriasis Product Portfolios and Specifications
Table 94. Ortho Dermatologics IL-17 Inhibitors for Psoriasis Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 95. Ortho Dermatologics Main Business
Table 96. Ortho Dermatologics Latest Developments
Table 97. LEO Pharma Basic Information, IL-17 Inhibitors for Psoriasis Manufacturing Base, Sales Area and Its Competitors
Table 98. LEO Pharma IL-17 Inhibitors for Psoriasis Product Portfolios and Specifications
Table 99. LEO Pharma IL-17 Inhibitors for Psoriasis Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 100. LEO Pharma Main Business
Table 101. LEO Pharma Latest Developments
Table 102. Kyowa Kirin Basic Information, IL-17 Inhibitors for Psoriasis Manufacturing Base, Sales Area and Its Competitors
Table 103. Kyowa Kirin IL-17 Inhibitors for Psoriasis Product Portfolios and Specifications
Table 104. Kyowa Kirin IL-17 Inhibitors for Psoriasis Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 105. Kyowa Kirin Main Business
Table 106. Kyowa Kirin Latest Developments
Table 107. Jiangsu Hengrui Pharmaceuticals Basic Information, IL-17 Inhibitors for Psoriasis Manufacturing Base, Sales Area and Its Competitors
Table 108. Jiangsu Hengrui Pharmaceuticals IL-17 Inhibitors for Psoriasis Product Portfolios and Specifications
Table 109. Jiangsu Hengrui Pharmaceuticals IL-17 Inhibitors for Psoriasis Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 110. Jiangsu Hengrui Pharmaceuticals Main Business
Table 111. Jiangsu Hengrui Pharmaceuticals Latest Developments
Table 112. Chongqing Genrix Biopharmaceutical Basic Information, IL-17 Inhibitors for Psoriasis Manufacturing Base, Sales Area and Its Competitors
Table 113. Chongqing Genrix Biopharmaceutical IL-17 Inhibitors for Psoriasis Product Portfolios and Specifications
Table 114. Chongqing Genrix Biopharmaceutical IL-17 Inhibitors for Psoriasis Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 115. Chongqing Genrix Biopharmaceutical Main Business
Table 116. Chongqing Genrix Biopharmaceutical Latest Developments
LIST OF FIGURES
Figure 1. Picture of IL-17 Inhibitors for Psoriasis
Figure 2. IL-17 Inhibitors for Psoriasis Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global IL-17 Inhibitors for Psoriasis Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global IL-17 Inhibitors for Psoriasis Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. IL-17 Inhibitors for Psoriasis Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. IL-17 Inhibitors for Psoriasis Sales Market Share by Country/Region (2025)
Figure 10. IL-17 Inhibitors for Psoriasis Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Bimelizumab
Figure 12. Product Picture of Secukinumab
Figure 13. Product Picture of Ixekizumab
Figure 14. Product Picture of Brodalumab
Figure 15. Product Picture of Vunakizumab
Figure 16. Product Picture of Xeligekimab
Figure 17. Product Picture of Other
Figure 18. Global IL-17 Inhibitors for Psoriasis Sales Market Share by Type in 2026
Figure 19. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Type (2021-2026)
Figure 20. IL-17 Inhibitors for Psoriasis Consumed in Hospital and Clinic
Figure 21. Global IL-17 Inhibitors for Psoriasis Market: Hospital and Clinic (2021-2026) & (K Units)
Figure 22. IL-17 Inhibitors for Psoriasis Consumed in Pharmacy
Figure 23. Global IL-17 Inhibitors for Psoriasis Market: Pharmacy (2021-2026) & (K Units)
Figure 24. IL-17 Inhibitors for Psoriasis Consumed in Other
Figure 25. Global IL-17 Inhibitors for Psoriasis Market: Other (2021-2026) & (K Units)
Figure 26. Global IL-17 Inhibitors for Psoriasis Sale Market Share by Application (2025)
Figure 27. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Application in 2026
Figure 28. IL-17 Inhibitors for Psoriasis Sales by Company in 2026 (K Units)
Figure 29. Global IL-17 Inhibitors for Psoriasis Sales Market Share by Company in 2026
Figure 30. IL-17 Inhibitors for Psoriasis Revenue by Company in 2026 ($ millions)
Figure 31. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Company in 2026
Figure 32. Global IL-17 Inhibitors for Psoriasis Sales Market Share by Geographic Region (2021-2026)
Figure 33. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Geographic Region in 2026
Figure 34. Americas IL-17 Inhibitors for Psoriasis Sales 2021-2026 (K Units)
Figure 35. Americas IL-17 Inhibitors for Psoriasis Revenue 2021-2026 ($ millions)
Figure 36. APAC IL-17 Inhibitors for Psoriasis Sales 2021-2026 (K Units)
Figure 37. APAC IL-17 Inhibitors for Psoriasis Revenue 2021-2026 ($ millions)
Figure 38. Europe IL-17 Inhibitors for Psoriasis Sales 2021-2026 (K Units)
Figure 39. Europe IL-17 Inhibitors for Psoriasis Revenue 2021-2026 ($ millions)
Figure 40. Middle East & Africa IL-17 Inhibitors for Psoriasis Sales 2021-2026 (K Units)
Figure 41. Middle East & Africa IL-17 Inhibitors for Psoriasis Revenue 2021-2026 ($ millions)
Figure 42. Americas IL-17 Inhibitors for Psoriasis Sales Market Share by Country in 2026
Figure 43. Americas IL-17 Inhibitors for Psoriasis Revenue Market Share by Country (2021-2026)
Figure 44. Americas IL-17 Inhibitors for Psoriasis Sales Market Share by Type (2021-2026)
Figure 45. Americas IL-17 Inhibitors for Psoriasis Sales Market Share by Application (2021-2026)
Figure 46. United States IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 47. Canada IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 48. Mexico IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 49. Brazil IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 50. APAC IL-17 Inhibitors for Psoriasis Sales Market Share by Region in 2026
Figure 51. APAC IL-17 Inhibitors for Psoriasis Revenue Market Share by Region (2021-2026)
Figure 52. APAC IL-17 Inhibitors for Psoriasis Sales Market Share by Type (2021-2026)
Figure 53. APAC IL-17 Inhibitors for Psoriasis Sales Market Share by Application (2021-2026)
Figure 54. China IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 55. Japan IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 56. South Korea IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 57. Southeast Asia IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 58. India IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 59. Australia IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 60. China Taiwan IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 61. Europe IL-17 Inhibitors for Psoriasis Sales Market Share by Country in 2026
Figure 62. Europe IL-17 Inhibitors for Psoriasis Revenue Market Share by Country (2021-2026)
Figure 63. Europe IL-17 Inhibitors for Psoriasis Sales Market Share by Type (2021-2026)
Figure 64. Europe IL-17 Inhibitors for Psoriasis Sales Market Share by Application (2021-2026)
Figure 65. Germany IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 66. France IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 67. UK IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 68. Italy IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 69. Russia IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 70. Middle East & Africa IL-17 Inhibitors for Psoriasis Sales Market Share by Country (2021-2026)
Figure 71. Middle East & Africa IL-17 Inhibitors for Psoriasis Sales Market Share by Type (2021-2026)
Figure 72. Middle East & Africa IL-17 Inhibitors for Psoriasis Sales Market Share by Application (2021-2026)
Figure 73. Egypt IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 74. South Africa IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 75. Israel IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 76. Turkey IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 77. GCC Countries IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 78. Manufacturing Cost Structure Analysis of IL-17 Inhibitors for Psoriasis in 2026
Figure 79. Manufacturing Process Analysis of IL-17 Inhibitors for Psoriasis
Figure 80. Industry Chain Structure of IL-17 Inhibitors for Psoriasis
Figure 81. Channels of Distribution
Figure 82. Global IL-17 Inhibitors for Psoriasis Sales Market Forecast by Region (2027-2032)
Figure 83. Global IL-17 Inhibitors for Psoriasis Revenue Market Share Forecast by Region (2027-2032)
Figure 84. Global IL-17 Inhibitors for Psoriasis Sales Market Share Forecast by Type (2027-2032)
Figure 85. Global IL-17 Inhibitors for Psoriasis Revenue Market Share Forecast by Type (2027-2032)
Figure 86. Global IL-17 Inhibitors for Psoriasis Sales Market Share Forecast by Application (2027-2032)
Figure 87. Global IL-17 Inhibitors for Psoriasis Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of IL-17 Inhibitors for Psoriasis
Figure 2. IL-17 Inhibitors for Psoriasis Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global IL-17 Inhibitors for Psoriasis Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global IL-17 Inhibitors for Psoriasis Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. IL-17 Inhibitors for Psoriasis Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. IL-17 Inhibitors for Psoriasis Sales Market Share by Country/Region (2025)
Figure 10. IL-17 Inhibitors for Psoriasis Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Bimelizumab
Figure 12. Product Picture of Secukinumab
Figure 13. Product Picture of Ixekizumab
Figure 14. Product Picture of Brodalumab
Figure 15. Product Picture of Vunakizumab
Figure 16. Product Picture of Xeligekimab
Figure 17. Product Picture of Other
Figure 18. Global IL-17 Inhibitors for Psoriasis Sales Market Share by Type in 2026
Figure 19. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Type (2021-2026)
Figure 20. IL-17 Inhibitors for Psoriasis Consumed in Hospital and Clinic
Figure 21. Global IL-17 Inhibitors for Psoriasis Market: Hospital and Clinic (2021-2026) & (K Units)
Figure 22. IL-17 Inhibitors for Psoriasis Consumed in Pharmacy
Figure 23. Global IL-17 Inhibitors for Psoriasis Market: Pharmacy (2021-2026) & (K Units)
Figure 24. IL-17 Inhibitors for Psoriasis Consumed in Other
Figure 25. Global IL-17 Inhibitors for Psoriasis Market: Other (2021-2026) & (K Units)
Figure 26. Global IL-17 Inhibitors for Psoriasis Sale Market Share by Application (2025)
Figure 27. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Application in 2026
Figure 28. IL-17 Inhibitors for Psoriasis Sales by Company in 2026 (K Units)
Figure 29. Global IL-17 Inhibitors for Psoriasis Sales Market Share by Company in 2026
Figure 30. IL-17 Inhibitors for Psoriasis Revenue by Company in 2026 ($ millions)
Figure 31. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Company in 2026
Figure 32. Global IL-17 Inhibitors for Psoriasis Sales Market Share by Geographic Region (2021-2026)
Figure 33. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Geographic Region in 2026
Figure 34. Americas IL-17 Inhibitors for Psoriasis Sales 2021-2026 (K Units)
Figure 35. Americas IL-17 Inhibitors for Psoriasis Revenue 2021-2026 ($ millions)
Figure 36. APAC IL-17 Inhibitors for Psoriasis Sales 2021-2026 (K Units)
Figure 37. APAC IL-17 Inhibitors for Psoriasis Revenue 2021-2026 ($ millions)
Figure 38. Europe IL-17 Inhibitors for Psoriasis Sales 2021-2026 (K Units)
Figure 39. Europe IL-17 Inhibitors for Psoriasis Revenue 2021-2026 ($ millions)
Figure 40. Middle East & Africa IL-17 Inhibitors for Psoriasis Sales 2021-2026 (K Units)
Figure 41. Middle East & Africa IL-17 Inhibitors for Psoriasis Revenue 2021-2026 ($ millions)
Figure 42. Americas IL-17 Inhibitors for Psoriasis Sales Market Share by Country in 2026
Figure 43. Americas IL-17 Inhibitors for Psoriasis Revenue Market Share by Country (2021-2026)
Figure 44. Americas IL-17 Inhibitors for Psoriasis Sales Market Share by Type (2021-2026)
Figure 45. Americas IL-17 Inhibitors for Psoriasis Sales Market Share by Application (2021-2026)
Figure 46. United States IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 47. Canada IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 48. Mexico IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 49. Brazil IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 50. APAC IL-17 Inhibitors for Psoriasis Sales Market Share by Region in 2026
Figure 51. APAC IL-17 Inhibitors for Psoriasis Revenue Market Share by Region (2021-2026)
Figure 52. APAC IL-17 Inhibitors for Psoriasis Sales Market Share by Type (2021-2026)
Figure 53. APAC IL-17 Inhibitors for Psoriasis Sales Market Share by Application (2021-2026)
Figure 54. China IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 55. Japan IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 56. South Korea IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 57. Southeast Asia IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 58. India IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 59. Australia IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 60. China Taiwan IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 61. Europe IL-17 Inhibitors for Psoriasis Sales Market Share by Country in 2026
Figure 62. Europe IL-17 Inhibitors for Psoriasis Revenue Market Share by Country (2021-2026)
Figure 63. Europe IL-17 Inhibitors for Psoriasis Sales Market Share by Type (2021-2026)
Figure 64. Europe IL-17 Inhibitors for Psoriasis Sales Market Share by Application (2021-2026)
Figure 65. Germany IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 66. France IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 67. UK IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 68. Italy IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 69. Russia IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 70. Middle East & Africa IL-17 Inhibitors for Psoriasis Sales Market Share by Country (2021-2026)
Figure 71. Middle East & Africa IL-17 Inhibitors for Psoriasis Sales Market Share by Type (2021-2026)
Figure 72. Middle East & Africa IL-17 Inhibitors for Psoriasis Sales Market Share by Application (2021-2026)
Figure 73. Egypt IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 74. South Africa IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 75. Israel IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 76. Turkey IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 77. GCC Countries IL-17 Inhibitors for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 78. Manufacturing Cost Structure Analysis of IL-17 Inhibitors for Psoriasis in 2026
Figure 79. Manufacturing Process Analysis of IL-17 Inhibitors for Psoriasis
Figure 80. Industry Chain Structure of IL-17 Inhibitors for Psoriasis
Figure 81. Channels of Distribution
Figure 82. Global IL-17 Inhibitors for Psoriasis Sales Market Forecast by Region (2027-2032)
Figure 83. Global IL-17 Inhibitors for Psoriasis Revenue Market Share Forecast by Region (2027-2032)
Figure 84. Global IL-17 Inhibitors for Psoriasis Sales Market Share Forecast by Type (2027-2032)
Figure 85. Global IL-17 Inhibitors for Psoriasis Revenue Market Share Forecast by Type (2027-2032)
Figure 86. Global IL-17 Inhibitors for Psoriasis Sales Market Share Forecast by Application (2027-2032)
Figure 87. Global IL-17 Inhibitors for Psoriasis Revenue Market Share Forecast by Application (2027-2032)
